Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: proteostasis regulators - Proteostasis Therapeutics

Drug Profile

Research programme: proteostasis regulators - Proteostasis Therapeutics

Alternative Names: PTI-130; PTI-C1811; PTI-P271

Latest Information Update: 21 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Proteostasis Therapeutics
  • Developer Biogen; Cystic Fibrosis Foundation Therapeutics; Harvard Medical School; Proteostasis Therapeutics
  • Class Small molecules
  • Mechanism of Action Alpha-synuclein inhibitors; Cystic fibrosis transmembrane conductance regulator stimulants; Protein folding modulators; Protein modulators; USP14 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease; Cystic fibrosis
  • No development reported Inflammation; Metabolic disorders; Neurodegenerative disorders; Parkinson's disease

Most Recent Events

  • 17 Dec 2018 Proteostasis Therapeutics signs an exclusive license agreement with Genentech
  • 28 Aug 2018 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA (PO)
  • 22 Dec 2017 Proteostasis Therapeutics plans a phase I trial for Cystic fibrosis (Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top